ADCP Bioassay Effector Cell FcγRIIa (H variant)-NFAT/Jurkat
CBP74106
| I. Background | |
|
ADCP（Antibody dependent cellular phagocytosis）是抗體依賴(lài)性細胞介導的吞噬作用。 是一種免疫消除機制，其憑借單克隆抗體（mAb）靶向腫瘤細胞，以促進(jìn)吞噬免疫細胞將 腫瘤細胞從體內清除。ADCP 由單核細胞、巨噬細胞、嗜中性粒細胞和樹(shù)突細胞通過(guò)表達 FcγRIIa（CD32a）、FcγRI（CD64）和 FcγRIIIa（CD16a）來(lái)介導來(lái)吞噬疾病細胞，研究表 明 FcγRIIa 是參與該過(guò)程的 FcγR 受體。 |
|
| II. Description | |
|
ADCP Bioassay Effector Cell FcγRIIa(H variant) -NFAT Jurkat 報告基因藥靶模型很好的 模擬了體內 ADCP 的信號轉導過(guò)程，原理見(jiàn)下圖所示。
Figure 1. ADCP Bioassay Effector Cell FcγRIIa(H variant) -NFAT Jurkat 細胞模型原理圖
|
|
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | FcγRIIa (H variant)-NFAT |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+1 μg/ml Puromycin+400 μg/ml Hygromycin B |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Human |
| Tissue: | Peripheral blood |
| Disease: | Childhood T acute lymphoblastic leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
|
Figure 2. Dose Response of Rituximab in ADCP Bioassay Effector Cell FcγRlla (H variant) -NFAT Jurkat (C2) with Raji. |
|
